

Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1498, 2005-01, pp. : 18-18
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Metformin may reduce the risk of cancer in patients with type 2 diabetes mellitus
Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. :








Fluoroquinolones reduce CHD risk in type 2 diabetes
Inpharma, Vol. 1, Iss. 1365, 2002-01 ,pp. :